European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma

Benedetto Bruno*, Ralph Wäsch, Monika Engelhardt, Francesca Gay, Luisa Giaccone, Mattia D’Agostino, Luis-Gerardo Rodríguez-Lobato, Sophia Danhof, Nico Gagelmann, Nicolaus Kröger, Rakesh Popat, Niels W. C. J. van de Donk, Evangelos Terpos, Meletios A. Dimopoulos, Pieter Sonneveld, Hermann Einsele, Mario Boccadoro

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.
Original languageEnglish
Pages (from-to)2054-2065
Number of pages12
Issue number8
Publication statusPublished - 1 Aug 2021

Cite this